The week in health tech, explained in plain English.Get the free newsletter →
June 11, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

AstraZeneca GLP-1 Pill Shows Promise in Obesity Trials

By Healthcare Technology News ·

AstraZeneca's experimental GLP-1 pill posted encouraging results in mid-stage obesity and diabetes trials, STAT News reports, putting the drugmaker on a path to compete in one of the most lucrative markets in medicine. The data suggest the oral treatment can meaningfully address both weight and blood sugar, though it is still early to judge how it measures against established options.

The race centers on convenience. Most GLP-1 blockbusters, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, are injectables. A pill that matches their effect could expand access, ease manufacturing constraints, and appeal to patients wary of needles. Lilly's oral orforglipron and Novo's oral options are also advancing, so AstraZeneca enters a crowded field.

For now, the key unknown is comparative efficacy and tolerability. STAT News notes it remains unclear how AstraZeneca's candidate stacks up against other oral treatments, and mid-stage results do not guarantee late-stage success. Larger trials will determine whether the company can carve out share in a market analysts expect to exceed $100 billion.

Sources

More in Finance

Finance

Incyte Pays $1.25B for Vega and Its Bleeding Disorder Drug

Incyte is acquiring Vega Therapeutics for $1.25 billion to gain a late-stage von Willebrand disease drug as patent expiration looms for its top product, Jakafi.

Why it matters: The deal shows how biopharma companies race to backfill pipelines and diversify ahead of major patent cliffs.

Finance

GSK to Buy Cancer Drugmaker Nuvalent for $10.6 Billion

GSK is acquiring Nuvalent for $10.6 billion to add late-stage targeted lung cancer drugs, the latest in a run of biopharma deals.

Why it matters: The deal shows how big drugmakers are spending billions on precision oncology to refill pipelines ahead of patent cliffs.

Finance

Gilead and Merck Split Trial Results in Busy Biotech Week

Gilead and Merck reported one trial win and one failure the same week, as AstraZeneca advanced a GLP-1 pill and GSK announced a $10.6 billion cancer acquisition.

Why it matters: Late-stage trial outcomes and multibillion-dollar deals from pharma's biggest players shape which therapies reach patients and where investor capital flows.